Beyondspring (NASDAQ:BYSI) announced its quarterly earnings results on Wednesday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.05), Fidelity Earnings reports.
Shares of NASDAQ BYSI opened at $17.73 on Friday. Beyondspring has a 12-month low of $13.06 and a 12-month high of $26.86. The firm’s 50-day moving average is $17.69 and its two-hundred day moving average is $17.40.
Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $41.00 price target on shares of Beyondspring in a report on Wednesday. Zacks Investment Research downgraded shares of Beyondspring from a “buy” rating to a “hold” rating in a report on Thursday, July 11th. Finally, ValuEngine downgraded shares of Beyondspring from a “buy” rating to a “hold” rating in a report on Thursday, September 5th.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Featured Story: Stock Portfolio Tracker
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.